Merck signs up to $3.3 billion cancer drug deal with China-based LaNova
By Leroy Leo (Reuters) -Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3...
Read moreBy Leroy Leo (Reuters) -Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3...
Read moreInvesting.com — K+S Group (ETR:SDFGn) on Thursday adjusted its financial guidance to the lower end of expectations, signaling a less...
Read more(Reuters) -General Mills said on Thursday it would buy Whitebridge Pet Brands’ North American premium cat feeding and pet treating...
Read moreShares in ESS Tech Inc (NYSE:GWH) tumbled nearly 19% in premarket trading Thursday after the energy storage solutions provider reported...
Read moreAMSTERDAM (Reuters) – ASML (AS:ASML) CEO Christoph Fouquet said on Thursday the ongoing boom in AI computer chips would help...
Read moreBy Pete Schroeder and Lananh Nguyen NEW YORK (Reuters) – As Wall Street financiers gathered in downtown Manhattan on Wednesday,...
Read moreInvesting.com — Evercore ISI has highlighted five technology stocks they believe are poised for strong performance into 2025: Apple (NASDAQ:AAPL), Arista...
Read moreBy Kirstin Ridley LONDON (Reuters) – Britain’s Financial Conduct Authority (FCA) on Wednesday softened proposals to publicly name some companies...
Read moreInvesting.com — Mastercard (NYSE:MA) on Wednesday issued new mid-term guidance for the 2025-2027 period, the company’s 8K filing showed. The...
Read moreZURICH (Reuters) – Swiss financial regulator FINMA said on Wednesday it will in future regularly review how it oversees UBS...
Read moreCopyright © 2025 Insightfulword.com. All Rights Reserved.